Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 5:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–3 of 3 matching trials from the live ClinicalTrials.gov search.
Conditions
Multiple Myeloma
Interventions
Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib, Daratumumab, Carfilzomib, Ixazomib, Elotuzumab, Clarithromycin, Belantamab Mafodotin, Mezigdomide
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
16
States / cities
Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 10 more
Conditions
AL Amyloidosis, Amyloidosis
Interventions
Belantamab mafodotin 2.5 mg/kg (8 weeks), Belantamab mafodotin 1.9 mg/kg (8 weeks), Belantamab mafodotin 1.4 mg/kg (12 weeks), Belantamab mafodotin 1.9 mg/kg (12 weeks), Belantamab mafodotin every 8 weeks or 12 weeks as determined by Part 1 recommended dosages, Belantamab mafodotin 1.0 mg/kg (12 weeks)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Nashville, Tennessee • Dallas, Texas • Salt Lake City, Utah
Conditions
Refractory Multiple Myeloma, Relapse Multiple Myeloma
Interventions
Belantamab mafodotin
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin